Ultimately, increased understanding of BACE1 and BACE2 expression and activity in pancreatic cancer will allow optimal selection of β-secretase inhibitors that have greater efficacy in reducing the viability of pancreatic cancer cells. Here, BACE1 is linked to familial pancreatic carcinoma.